FORTIS HEALTHCARE LTD. - 532843 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants), Regulations 2018 as amended from time to time, please find enclosed herewith certificates received from Kfin Technologies Limited (formerly known as Kfin Technologies Private Limited), the Registrar and Transfer Agent, for the quarter ended September 30, 2023. FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to Reg. 30 of SEBI LODR Regulations 2015 read with SEBI Circular dated July 13, 2023, this is to inform you that the Company has received a letter dated October 6, 2023 from Northern TK Venture Pte Ltd (Promoter of the Company) intimating about withdrawal of nomination of Mr. Joerg Ayrle from the Board of the Company and accordingly, Mr. Joerg Ayrle has ceased to be the Non-Executive Non-Independent Director of the Company. Detailed disclosure in this regard is enclosed. FORTIS HEALTHCARE LTD. - 532843 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 In Relation To Filing Of Draft Red Herring Prospectus By Agilus Diagnostics Limited, A Material Subsidiary Of The Company.
This is in continuation to intimation dated August 4, 2023 in relation to initiation of initial public offering (IPO) process, by way of an offer for sale by Agilus Diagnostics Limited (Agilus) of such number of equity shares as may be offered by certain existing and eligible shareholders of Agilus in the IPO, in accordance with applicable laws. In this regard, and pursuant to Regulation 30 of SEBI Listing Regulations, this is to inform you that Agilus has, on September 29, 2023, filed the draft red herring prospectus (the DRHP) with the Securities and Exchange Board of India. Detailed disclosure is enclosed herewith in this regard. FORTIS HEALTHCARE LTD. - 532843 - Closure of Trading Window
With reference to the provisions of Policy / Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in shares of the Company is closed from September 30, 2023 till 48 hours from declaration of un-audited financial results for the quarter and period ending on September 30, 2023.
Fortis Healthcare gains on plans to acquire Kolkata-based realty firm
Through the acquisition of Artistery Properties, the pharma-company is also set to gain ownership of a building owned by the company located adjacent to the Fortis Hospital at Anandpur in Kolkata. FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Acquisition
Pursuant to the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that the Board of the Company at its meeting held today i.e. September 25, 2023, accorded its consent to enter into a Share Purchase Agreement for acquiring 99.9% stake equivalent to 9990 equity shares in Artistery Properties Private Limited ("Artistery"). Detailed disclosure is enclosed. FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Reg. 30 of SEBI LODR, this is to inform you that based on the recommendation of Nomination and Remuneration Committee of the Company, the Board of Directors of the Company has approved the appointment of Mr. Ashok Pandit as an Additional Director (Non-Executive & Non-Independent) of the Company w.e.f. September 13, 2023. The detailed disclosure in this regard is enclosed herewith. FORTIS HEALTHCARE LTD. - 532843 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
With reference to Postal Ballot Notice dated August 4, 2023, proceeding and voting results along with scrutinizers report is attached. FORTIS HEALTHCARE LTD. - 532843 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
With reference to the Postal Ballot Notice dated August 4, 2023, proceeding and voting results along with scrutinizer reports are attached.
Fortis Healthcare gains 3%; Nomura sees 20% upside, raises price target
Despite concerns over Fortis Healthcare's EBITDA margin lagging peers, Nomura expects the healthcare firm to the catch up on operating metrics in the near-to-medium term